Additional file 4: Table S2. of Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

Lacosta, Ana-María; Pascual-Lucas, María; Pesini, Pedro; Casabona, Diego; Pérez-Grijalba, Virginia; Marcos-Campos, Iván; Sarasa, Leticia; Canudas, Jesus; Badi, Hassnae; Monleón, Inmaculada; San-José, Itziar; Munuera, Josep; Rodríguez-Gómez, Octavio; Abdelnour, Carla; Lafuente, Asunción; Buendía, Mar; Boada, Mercè; Tárraga, Lluis; Ruiz, Agustín; Sarasa, Manuel

doi:10.6084/m9.figshare.5835027.v1

13195_2018_340_MOESM4_ESM.docx (15.38 kB)

Additional file 4: Table S2. of Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

journal contribution

posted on 2018-01-29, 05:00 authored by Ana-María Lacosta, María Pascual-Lucas, Pedro Pesini, Diego Casabona, Virginia Pérez-Grijalba, Iván Marcos-Campos, Leticia Sarasa, Jesus Canudas, Hassnae Badi, Inmaculada Monleón, Itziar San-José, Josep Munuera, Octavio Rodríguez-Gómez, Carla Abdelnour, Asunción Lafuente, Mar Buendía, Mercè Boada, Lluis Tárraga, Agustín Ruiz, Manuel Sarasa

Relationship of adverse events (AEs) with the treatment. (DOCX 15 kb)

Funding

Araclon Biotech

History

Usage metrics

Keywords

Alzheimer’s disease Amyloid-β Aβ Immunotherapy ABvac40 Phase I

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 4: Table S2. of Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

Funding

Araclon Biotech

History

Usage metrics

Categories

Keywords

Licence

Exports